This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Data From Clinical Trials Show Pluristem’s Placenta-Derived Cell Therapy Is Safe And Improves Quality Of Life And Efficacy Measurements In Patients With Critical Limb Ischemia

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today reported that data from clinical trials show the Company’s placenta-derived cell therapy, PLX-PAD, is safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD).

CLI Patients and Doctors Involved in Trials Share Their Stories on Video; CLICK HERE to Watch

The three-month follow-up data involved 21 patients afflicted with CLI in two open-label, dose-escalation, Phase I clinical trials conducted at Duke University Medical Center, Stanford University Medical Center, the Center for Therapeutic Angiogenesis in Birmingham, Alabama and St. Franziskus Hospital, supported by the Charité - University Medicine Berlin. The results of these clinical trials have enabled Pluristem to select the target treatment dose of PLX-PAD for additional studies focused on the cell therapy’s efficacy. Pluristem has communicated with both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) concerning the design of an optimal multinational study that will support an approval for marketing PLX-PAD for the treatment of CLI.

The two Phase I studies were designed to evaluate the safety of PLX-PAD cells and included accessing the patient’s immunological profile before and after the local administration of PLX-PAD. In addition, efficacy parameters were assessed and five different doses of PLX-PAD were evaluated. These studies were performed in parallel in the EU and USA and represent the first time that Pluristem’s PLX-PAD cells were administered to humans. PLX-PAD cells are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.

Results included the findings that PLX-PAD cells can be administered safely as an “off-the-shelf” product without a need for matching between donor and patient. Additionally, efficacy was demonstrated across all doses with a statistically significant improvement noted in the pain score and quality of life. The intermediate dose also showed a statistically significant improvement in the Ankle Brachial Index (ABI), a measure of blood flow.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs